Combination vs. Sequential Chemotherapy in Advanced Breast Cancer
Author Information
Author(s): R.T. Chlebowski, R.V. Smalley, J.M. Weiner, L.E. Irwin, A.A. Bartolucci, J.R. Bateman
Primary Institution: The Western Cancer Study Group and the Southeastern Cancer Study Group
Hypothesis
Can sequential single agent therapy provide comparable survival to combination treatment in advanced breast cancer patients?
Conclusion
Combination chemotherapy offers significant survival benefits for patients with liver involvement, but sequential therapy is comparable for those without liver metastases.
Supporting Evidence
- Combination treatment resulted in a 46% response rate compared to 25% for sequential treatment.
- Patients without liver involvement had similar survival rates regardless of treatment type.
- Patients with liver involvement had a median survival of 10.1 months with combination therapy versus 5.3 months with sequential therapy.
Takeaway
This study looked at two ways to treat advanced breast cancer: using a mix of drugs at the same time or using them one after the other. It found that for most patients, taking the drugs one at a time works just as well as taking them all together.
Methodology
Patients were randomized into two groups to receive either combination chemotherapy or sequential single agent chemotherapy, with data analyzed from both trials.
Potential Biases
Potential bias in patient selection and treatment assignment could affect the results.
Limitations
The study may not account for all variables affecting survival, and the long-term effects of combination therapy could have adverse impacts.
Participant Demographics
Patients included those with advanced breast cancer, with a mix of liver involvement and other metastatic sites.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website